Clinical bottom line
Pediatric vestibular migraine (PVM) is an increasingly recognized cause of episodic vertigo and dizziness in children and adolescents, with diagnostic criteria evolving to improve clinical identification. Recent advances emphasize a multimodal approach combining detailed clinical assessment with targeted investigations to exclude mimics. Management strategies now include both pharmacological and non-pharmacological interventions, with emerging evidence supporting the use of neuromodulation devices and tailored migraine prophylaxis in select pediatric populations. Despite progress, the evidence base remains limited by small cohort sizes and heterogeneity in diagnostic standards, underscoring the need for further validation in pediatric-specific trials.
What the evidence shows
Diagnosis of PVM relies primarily on clinical criteria adapted from adult vestibular migraine definitions, incorporating episodic vestibular symptoms temporally associated with migraine features such as headache, photophobia, or phonophobia (Li et al., 2015; Widdershoven et al., 2025). Recent consensus efforts have refined these criteria to enhance specificity in children, who may present with atypical or subtle migraine symptoms (Gillard et al., 2023). Diagnostic workup typically involves exclusion of alternative vestibular disorders through vestibular function testing and neuroimaging when indicated (Schettino et al., 2019; 2026).
Pharmacological management in pediatric populations is extrapolated largely from adult migraine literature, with agents such as beta-blockers, calcium channel blockers, and antiepileptics used off-label for prophylaxis (DiBlasi et al., 2026). DiBlasi and colleagues (2026) reported that individualized pharmacotherapy within a pediatric vestibular program led to symptomatic improvement in a majority of children, though controlled trial data remain sparse. Non-pharmacological interventions, including lifestyle modification and vestibular rehabilitation, are recommended adjuncts.
Notably, non-invasive neuromodulation devices have gained attention as emerging therapies for acute and preventive migraine treatment. The International Headache Society’s 2025 evidence-based guidelines highlight several devices with potential utility in pediatric migraine, though specific data for vestibular migraine in children are limited (Yuan et al., 2025). These modalities may offer a favorable safety profile and warrant further study in this population.
Caveats and uncertainty
The pediatric vestibular migraine literature is hindered by variable diagnostic criteria and limited large-scale prospective studies, leading to potential under- or over-diagnosis. Many pharmacological treatments lack robust pediatric-specific efficacy and safety data, with most recommendations extrapolated from adult studies or small case series (DiBlasi et al., 2026). The heterogeneity of vestibular symptoms and overlap with other vestibular disorders complicate diagnosis and management.
Neuromodulation devices, while promising, require validation in rigorously designed pediatric trials to establish efficacy, optimal protocols, and long-term safety (Yuan et al., 2025). Additionally, the natural history of PVM and predictors of treatment response remain incompletely understood, limiting personalized management strategies.
How this may change practice
Clinicians should maintain a high index of suspicion for vestibular migraine in children presenting with episodic vertigo and migraine features, applying updated pediatric-specific diagnostic criteria to improve recognition (Widdershoven et al., 2025). A comprehensive vestibular assessment and exclusion of alternative diagnoses remain essential.
Management may increasingly incorporate individualized pharmacological prophylaxis guided by emerging pediatric data, alongside vestibular rehabilitation and lifestyle counseling. Awareness of neuromodulation devices as potential adjunctive or alternative therapies may expand treatment options, particularly for patients with refractory symptoms or contraindications to medications.
Otolaryngologists and pediatric neurologists should collaborate closely to optimize diagnostic accuracy and therapeutic outcomes, while contributing to prospective research efforts to strengthen the evidence base for pediatric vestibular migraine.